miRNA在胸膜间皮瘤耐药中的作用研究进展
x

请在关注微信后,向客服人员索取文件

篇名: miRNA在胸膜间皮瘤耐药中的作用研究进展
TITLE: Research progress on the role of miRNA in drug resistance of pleural mesothelioma
摘要: 胸膜间皮瘤(PM)是来源于胸膜的一种罕见恶性肿瘤,大多数患者确诊时已为晚期,患者总体生存率低。微RNA(miRNA)作为肿瘤表观遗传修饰的关键调节因子,与PM耐药性之间有着彼此交错的互作网络。PM对化疗药物的耐药机制包括增加药物外流、减少药物摄取、增强DNA修复、改变药物靶点等;对靶向治疗药物的耐药机制则包括激活替代的信号通路、建立有利的肿瘤微环境、触发上皮-间充质转化等。miRNA在上述耐药机制中发挥了重要作用,部分miRNA可增强癌细胞的药物敏感性,但部分miRNA则具有增强耐药性的作用。鉴于这些关键调控作用,通过使用miRNA拮抗剂或miRNA模拟物靶向纠正耐药形成过程中内源性miRNA的表达失调,可能是逆转PM耐药一种有效的治疗策略。
ABSTRACT: Pleural mesothelioma (PM) is a rare malignant tumor originating from the pleura. Most patients are already in the advanced stage at the time of diagnosis, resulting in a low overall survival rate. MicroRNA (miRNA), as key regulators of tumor epigenetic modification, have an intertwined interactive network with PM drug resistance. The mechanisms of drug resistance in PM to chemotherapeutic drugs include increasing drug efflux, reducing drug intake, enhancing DNA repair, and altering drug targets. The mechanisms of resistance to targeted therapy drugs include activating alternative signaling pathways, establishing a favorable tumor microenvironment, and triggering epithelial-mesenchymal transition. MiRNA plays a key part in the aforementioned resistance mechanisms, with some miRNAs promoting the drug sensitivity of cancer cells, while others contribute to increased drug resistance. In light of these key regulatory functions, targeting the dysregulated expression of endogenous miRNAs in the process of resistance formation using miRNA antagonists or miRNA mimics may be an effective therapeutic strategy to reverse drug resistance in PM.
期刊: 2024年第35卷第22期
作者: 王心萌;李锦松;林亚茹;唐洗敏;普元倩;自加吉;熊伟
AUTHORS: WANG Xinmeng,LI Jinsong,LIN Yaru,TANG Ximin,PU Yuanqian,ZI Jiaji,XIONG Wei
关键字: 微RNA;胸膜间皮瘤;靶向治疗;耐药
KEYWORDS: miRNA; pleural mesothelioma; targeted therapy; drug resistance
阅读数: 12 次
本月下载数: 3 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!